A joint Germany-China study on M1/M2, etc immunoactivation potential by chemotherapeutics like paclitaxel in cancer treatment adds validation to Navidea pre clinical trial for TAMS reprogramming using paclitaxel
The abstract, “Synthetic CD206 Targeted Constructs Carrying Paclitaxel
or Novel Bisphosphonate Payloads Alter Macrophages Towards
Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the
Efficacy of anti-CTLA4 in CT26 Tumors” (Abstract #1161), will be
presented as a poster on November 10, 9 am to 9 pm in the conference
center’s poster hall. Further details of the abstract will be announced
in a future press release once the meeting embargo is lifted.